University of Southern California at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

University of Southern California takes part in 5 sessions at CTAD 2026 in Boston. Its program spans anti-amyloid antibody safety, disease modification and the recruitment of Latino older adults into research. Its work also covers tau disaggregase drugs and financial vulnerability as an early sign of Alzheimer's disease.

Organization	CTAD 2026 Attendance
University of Southern California Los Angeles, California
	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Characterization of Serious ARIA Events from Approved Amyloid Antibodies: Real World Analysis of Spontaneous Reports FDA Adverse Event Monitoring System (AEMS) (P148) Anti-amyloid and anti-tau therapies · Real-world data and access Talk Tue Nov 17 9:50am Clinical Evidence for Disease Modification by Amyloid-Targeting Antibodies Anti-amyloid and anti-tau therapies Poster Wed Nov 18 7:15am–5:30pm Mechanistic and Therapeutic Evaluation of Small Molecule Tau Disaggregases as a treatment for Alzheimer’s Disease (P346) Anti-amyloid and anti-tau therapies Poster Thu Nov 19 7:15am–5:00pm Financial Vulnerability as an Early Functional Marker of Alzheimer’s Disease: From Neuroimaging to Plasma Biomarker Considerations (P401) Trial design and endpoints · Prevention and early disease Poster Thu Nov 19 7:15am–5:00pm Optimizing Recruitment Resources for Underrepresented Latino Older Adults in Alzheimer’s Research: A Randomized Trial of Community-Based Recruitment (P484) Trial design and endpoints

Organization

CTAD 2026 Attendance

University of Southern California

Los Angeles, California

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Characterization of Serious ARIA Events from Approved Amyloid Antibodies: Real World Analysis of Spontaneous Reports FDA Adverse Event Monitoring System (AEMS) (P148)

Anti-amyloid and anti-tau therapies · Real-world data and access

Talk

Tue Nov 17
9:50am

Clinical Evidence for Disease Modification by Amyloid-Targeting Antibodies

Anti-amyloid and anti-tau therapies

Poster

Wed Nov 18
7:15am–5:30pm

Mechanistic and Therapeutic Evaluation of Small Molecule Tau Disaggregases as a treatment for Alzheimer’s Disease (P346)

Anti-amyloid and anti-tau therapies

Poster

Thu Nov 19
7:15am–5:00pm

Financial Vulnerability as an Early Functional Marker of Alzheimer’s Disease: From Neuroimaging to Plasma Biomarker Considerations (P401)

Trial design and endpoints · Prevention and early disease

Poster

Thu Nov 19
7:15am–5:00pm

Optimizing Recruitment Resources for Underrepresented Latino Older Adults in Alzheimer’s Research: A Randomized Trial of Community-Based Recruitment (P484)

Trial design and endpoints

Instantly find 20 buyers from University of Southern California

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction